Dimensional Fund Advisors LP Takes $205,000 Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Dimensional Fund Advisors LP bought a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 54,114 shares of the company's stock, valued at approximately $205,000. Dimensional Fund Advisors LP owned approximately 0.08% of Amylyx Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in AMLX. Blue Trust Inc. boosted its position in Amylyx Pharmaceuticals by 232.1% during the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock valued at $26,000 after purchasing an additional 4,883 shares during the period. XTX Topco Ltd boosted its position in Amylyx Pharmaceuticals by 12.0% during the 4th quarter. XTX Topco Ltd now owns 53,376 shares of the company's stock valued at $202,000 after purchasing an additional 5,704 shares during the period. Fox Run Management L.L.C. acquired a new position in Amylyx Pharmaceuticals during the 4th quarter valued at approximately $45,000. RPO LLC acquired a new position in Amylyx Pharmaceuticals during the 4th quarter valued at approximately $46,000. Finally, EntryPoint Capital LLC acquired a new position in Amylyx Pharmaceuticals during the 4th quarter valued at approximately $53,000. Institutional investors and hedge funds own 95.84% of the company's stock.

Amylyx Pharmaceuticals Stock Down 0.9%

AMLX stock traded down $0.05 during trading on Friday, reaching $5.31. 906,493 shares of the company's stock were exchanged, compared to its average volume of 1,221,852. Amylyx Pharmaceuticals, Inc. has a 1-year low of $1.58 and a 1-year high of $7.27. The company's fifty day moving average price is $4.31 and its 200-day moving average price is $4.20. The firm has a market cap of $473.34 million, a PE ratio of -1.39 and a beta of -0.60.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.03. As a group, sell-side analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Mizuho boosted their price objective on Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the company an "outperform" rating in a research report on Wednesday, May 14th. Leerink Partnrs upgraded Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 6th. HC Wainwright boosted their price objective on Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Finally, Leerink Partners upgraded Amylyx Pharmaceuticals from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $4.00 to $10.00 in a research report on Wednesday, May 7th. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $9.83.

Insiders Place Their Bets

In other news, Director Bernhardt G. Zeiher acquired 10,000 shares of the business's stock in a transaction dated Thursday, March 20th. The stock was acquired at an average price of $3.70 per share, for a total transaction of $37,000.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at $37,000. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, insider Camille L. Bedrosian sold 12,425 shares of the company's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $3.47, for a total value of $43,114.75. Following the completion of the sale, the insider now owns 194,375 shares of the company's stock, valued at approximately $674,481.25. This trade represents a 6.01% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,980 shares of company stock worth $168,627. 11.70% of the stock is owned by company insiders.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.